Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1486 Articles

Jon C. Ogg | Dec 10, 2014 at 10:35 AM EST

What a Generic Celebrex Means for Pfizer and for Actavis

While this was generally a known event coming down the pipe, arthritis drug Celebrex now has a generic competitor in…

Paul Ausick | Dec 5, 2014 at 4:01 PM EST

The 4 Stocks That Carried the Market on Friday

thinkstockDecember 4, 2014: Markets opened higher on Friday after the federal government released a better-than-expected report on employment. Job gains…

Lee Jackson | Dec 3, 2014 at 8:25 AM EST

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

The U.S. equity market is still a great place to be, and the analysts at Jefferies may have a good…

Lee Jackson | Dec 1, 2014 at 8:25 AM EST

Analyst’s 4 Stocks to Buy With Imminent Catalysts

A new report from Jefferies focuses on four stocks to buy that have impending events that could make a difference…

Paul Ausick | Nov 25, 2014 at 4:01 PM EST

The 4 Stocks That Lifted the DJIA

thinkstockNovember 25, 2014: Markets opened higher on Tuesday but the gains were small heading into the long weekend. The second…

Paul Ausick | Nov 18, 2014 at 9:10 AM EST

Companies Spending the Most on R&D

For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.

Chris Lange | Oct 27, 2014 at 12:40 PM EDT

Pain Therapeutics and Durect Stung by Pfizer Move

Durect and Pain Therapeutics have been stung by Pfizer's decision to discontinue to develop Remoxy.

Paul Ausick | Oct 24, 2014 at 4:01 PM EDT

The 4 DJIA Stocks That Boosted the Market

thinkstockOctober 24, 2014: Markets opened slightly higher on Friday, and following a short trip below the break-even line, marched higher…

Jon C. Ogg | Oct 24, 2014 at 8:05 AM EDT

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

Pfizer's new buyback is simply too large and too significant to ignore, and it might jokingly be called "on Viagra."

Paul Ausick | Oct 16, 2014 at 4:01 PM EDT

The 4 Stocks That Held the DJIA Down

thinkstockOctober 16, 2014: Markets opened lower on Thursday following a sharp drop in crude oil prices overnight and a better-than-expected…

Jon C. Ogg | Oct 10, 2014 at 9:30 AM EDT

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Short sellers have decided to get out of some of the go-to defensive stocks with high-dividend yields in late September.

Lee Jackson | Oct 1, 2014 at 8:25 AM EDT

Merrill Lynch’s Key Stock Picks for the Fourth Quarter

With or without mid-term elections, the last quarter of 2014 and January of next year could be a bonanza for…

Jon C. Ogg | Sep 25, 2014 at 2:15 PM EDT

5 Defensive Stocks Largely Avoiding the Sell-Off

24/7 Wall St. has tracked several defensive stocks that are not down near as much as the market on Thursday.

Jon C. Ogg | Sep 25, 2014 at 9:50 AM EDT

Short Sellers Run for Cover in Defensive High-Yield Dividend Stocks

24/7 Wall St. takes look at what is happening in the short interest of the go-to high-dividend defensive stocks.

Jon C. Ogg | Sep 23, 2014 at 1:30 PM EDT

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

The U.S. Treasury has finally made its proposed effort to deal with the waves of corporate tax inversions that have…

1 … 62 63 64 65 66 … 100

Pfizer : PFE

All Pfizer Articles

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Pain Therapeutics and Durect Stung by Pfizer Move

The 4 DJIA Stocks That Boosted the Market

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

The 4 Stocks That Held the DJIA Down

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Merrill Lynch’s Key Stock Picks for the Fourth Quarter

5 Defensive Stocks Largely Avoiding the Sell-Off

Short Sellers Run for Cover in Defensive High-Yield Dividend Stocks

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

Pfizer : PFE

All Pfizer Articles

What a Generic Celebrex Means for Pfizer and for Actavis

The 4 Stocks That Carried the Market on Friday

2014’s Underperforming Large-Cap Stocks That Could Be 2015 Winners

Analyst’s 4 Stocks to Buy With Imminent Catalysts

The 4 Stocks That Lifted the DJIA

Companies Spending the Most on R&D

Pain Therapeutics and Durect Stung by Pfizer Move

The 4 DJIA Stocks That Boosted the Market

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

The 4 Stocks That Held the DJIA Down

Short Sellers Getting Smart in Defensive High-Yield Dividend Stocks

Merrill Lynch’s Key Stock Picks for the Fourth Quarter

5 Defensive Stocks Largely Avoiding the Sell-Off

Short Sellers Run for Cover in Defensive High-Yield Dividend Stocks

Is Treasury Plan for Tax Inversion REALLY Trouble for Merger Stocks?

Wall Street CIO: The AI Trade is “Technically Unsustainable.” Buy These Two Industries Instead.

Wall Street Strategist: SpaceX Will Force a Major Stock Market Repositioning. Buy These Stocks Instead.

3 Dividend Stocks Built for Retirement to Buy in June

Featured Reads

Retired Couple With $1.9 Million Faces $4,800 IRMAA Surprise After Stock Sale

A $900,000 Nest Egg at 65 Only Translates to About $36,000 in Real Annual Spending After Taxes and Inflation